Resources Repository
-
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Science/Technology | Infectious Diseases | Costing Methods | Health Outcomes | Test Performance | Decision Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Government/Law | North America -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Science/Technology | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | Technology Assessment | Operations Research | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Global -
Resource PortalWeb Portal, Teaching Resource 2024MIDAS
MIDAS is a collaborative network of research scientists who use computational, statistical and mathematical models …
MIDAS is a collaborative network of research scientists who use computational, statistical and mathematical models to understand infectious disease dynamics and thereby assist the nation to prepare for, detect and respond to infectious disease threats. Midas focuses on research topics such as: Dynamics of emergence and spread of pathogens; Identification and surveillance of infectious diseases; Effectiveness and consequences of intervention strategies; Host/pathogen interactions; Ecological, climatic, economic and evolutionary dimensions of infectious diseases; The roles of behavior and behavioral adaptation in…
Cost-Effectiveness Analysis | Health/Medicine | Climate/Environment | Science/Technology | Infectious Diseases | Mathematical Models | Dynamic Transmission | Calibration/Validation | Dynamic Simulation | Risk Analysis | Technology Assessment | Health Systems | Policy/Regulation | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Conceptual Mapping | Quantitative Literacy -
ArticlePublication 2016Rotavirus Vaccines Contribute Towards UHC in A Mixed Public–Private Healthcare System
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from …
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from the household’s perspective. The authors found that rotavirus vaccination reduces rotavirus episodes and expenditure substantially and provides financial risk protection to all income groups. Although the rich are paying more out of pocket than the poor by utilizing more expensive healthcare, the poor are paying more in proportion to household income. Poverty reduction benefits are concentrated amongst the poorest two…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Science/Technology | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Child/Nutrition | Social Determinants | Health Systems | Asia & Pacific -
ArticlePublication 2015Achieving a 'Grand Convergence' in Global Health
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment …
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment case for a grand convergence in health outcomes globally. In support of the drafting of the Sustainable Development Goals (SDGs), this paper presents estimates of what the grand convergence investment case might achieve—and what investment would be required—by 2030. The authors start with a country-based (bottom-up) analysis of the costs and impact of…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Science/Technology | Global Governance | Costing Methods | Health Outcomes | Health Systems | Global -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Cost-Effectiveness Analysis | Health/Medicine | Climate/Environment | Economics/Finance | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Child/Nutrition | Social Determinants | Environmental Health | Health Systems | Sub-Saharan Africa -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Science/Technology | Infectious Diseases | Costing Methods | Health Outcomes | Chronic Disease/Risk | Health Systems | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Science/Technology | Infectious Diseases | Mathematical Models | Microsimulation | Calibration/Validation | Chronic Disease/Risk | Health Systems | Asia & Pacific -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Science/Technology | Infectious Diseases | Mathematical Models | Decision Analysis | Chronic Disease/Risk | Global